JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 17, 2006; DOI: 10.1124/jpet.106.110080


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.110080v1
319/2/898    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ehrlich, J. R.
Right arrow Articles by Gogelein, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ehrlich, J. R.
Right arrow Articles by Gogelein, H.


Received for publication June 29, 2006.
Revised August 15, 2006.
Accepted for publication August 15, 2006.

Properties of a Time-dependent Potassium Current in Pig Atrium - Evidence for a Role of Kv1.5 in Repolarization

Joachim R. Ehrlich 1*, Christin Hoche 2, Pierre Coutu 3, Christiane Metz-Weidmann 4, Werner Dittrich 4, Stefan H. Hohnloser 2, Stanley Nattel 3, Heinz Gogelein 4

1 Div. of Cardiology 2 Div. of Cardiology, J.W. Goethe-University 3 Montreal Heart Institute 4 Sanofi-Aventis, Frankfurt

* Address correspondence to: E-mail: j.ehrlich{at}em.uni-frankfurt.de

Abstract

Cardiac electrical activity is modulated by potassium currents. Pigs have been used for anti-arrhythmic drug-testing, but only sparse data exist regarding porcine atrial ionic electrophysiology. Here, we used electrophysiological, molecular and pharmacological tools to characterize a prominent porcine outward K+ current (termed IK,PO) in atrial cardiomyocytes isolated from adult pigs. IK,PO activated rapidly (time-to-peak at +60 mV: 2.1±0.2 ms), inactivated slowly ({tau}f=45±10, {tau}s=215±28 ms) and showed very slow recovery ({tau}f=1.54±0.73 sec; {tau}s=7.91±1.78 sec, n=9, 36° C). Activation and inactivation were voltage-dependent and current properties were consistent with predominant K+-conductance. Neurotoxins (heteropodatoxin, hongatoxin, BDS) that block Kv4.x, Kv1.1, 1.2, 1.3 and 3.4 in a highly-selective manner, as well as H2O2 and TEA, did not affect the current. Drugs with Kv1.5-blocking properties (flecainide, perhexiline and the novel atrial-selective anti-arrhythmic AVE0118) inhibited IK,PO (IC50 132±47, 17±10 and 1.25±0.62 µM, respectively). 4-Aminopyridine suppressed the current and accelerated its decay, reducing charge-carriage with an IC50 of 39±15 µM. Porcine-specific Kv channel-subunit sequences were cloned to permit real-time quantitative RT-PCR on RNA extracted from isolated cardiomyocytes, which showed much greater abundance of Kv1.5 mRNA compared to Kv1.4, Kv4.2 and Kv4.3. Action potential recordings showed that IK,PO-inhibition with 0.1 mM 4-AP delayed repolarization (e.g., APD at -50 mV increased from 45±9 to 69±5 ms at 3 Hz, P<0.05). In conclusion, porcine atrium displays a current that is involved in repolarization, inactivates more slowly than classical Ito, is associated with strong Kv1.5 expression and shows a pharmacological profile typical of Kv1.5-dependent currents.


Key words: AVE0118, IKur, action potential, atrial fibrillation, cardiomyocyte, potassium current


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
J. R. Ehrlich, P. Biliczki, S. H. Hohnloser, and S. Nattel
Atrial-Selective Approaches for the Treatment of Atrial Fibrillation
J. Am. Coll. Cardiol., February 26, 2008; 51(8): 787 - 792.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.